27 Sep 2025 | 5 Mins Read
HSBC sees limited earnings risk for Sun Pharma in US tariff turbulence
Flipitmoney
Sun Pharma, India's largest drugmaker, could face limited earnings impact from US President Donald Trump's 100% import tariff on branded pharmaceuticals. Of its $1.2 billion global sales in patented products, $1.1 billion comes from the US, amounting to 17% of Sun Pharma's total revenue. HSBC outlines potential mitigation strategies, including relocating manufacturing.